NVS - Novartis ending development of phase 3 KRAS lung cancer drug - report
2024-05-30 11:54:09 ET
More on Novartis
- Novartis: Buy This Blue-Chip Dividend Stock On Sale Now
- Novartis: Strong Start To The Year With Beat-And-Raise First Quarter Results
- Novartis reports Phase 3 results for IgA nephropathy treatment
- Novartis AG (NVS) Q1 2024 Earnings Call Transcript
- ADHD diagnoses increasing, becoming an 'expanding public health concern': CDC